We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Focal therapy for prostate cancer – when to refer?
- Authors
Rokan, Nadia; Reddy, Deepika; Dudderidge, Tim
- Abstract
Focal therapy (FT) for prostate cancer, using high-intensity focused ultrasound, cryotherapy, and irreversible electroporation, has been available in the UK for over a decade under National Institute for Health and Care Excellence (NICE) guidance. The availability of FT in the UK is expanding with the launch of the PART trial, which aims to recruit 800 patients from multiple centers. FT aims to provide oncological control for patients with intermediate-risk localized prostate cancer while minimizing the impact on genitourinary function. Ideal patients for FT are those with significant prostate cancer visible on multiparametric MRI and concordant cancer on biopsies. Follow-up involves regular monitoring and additional treatment may be required for some patients. FT has been shown to provide comparable oncological control to radical prostatectomy, with low rates of progression to metastatic disease and minimal impact on urinary and erectile function. The NICE has approved several FTs, and patients should be advised about these options and referred to specialist centers for consultation.
- Subjects
PROSTATE cancer; CANCER treatment; HIGH-intensity focused ultrasound; ENDORECTAL ultrasonography; RADICAL prostatectomy; PROSTATE cancer patients
- Publication
BJU International, 2024, Vol 133, Issue 6, p665
- ISSN
1464-4096
- Publication type
Article
- DOI
10.1111/bju.16315